Drug Trial Radar · NCT00094497
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
304
Actual
Start
Jun 2004
Primary completion
Dec 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- Collaborative Group for Adrenocortical Carcinoma TreatmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- German Federal Ministry of Education and Research; National Cancer Institute (NCI)
- First posted
- Oct 20, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection.
Conditions
- Carcinoma, Adrenal Cortical
Interventions
EtoposideDrug
DoxorubicinDrug
CisplatinDrug
StreptozotocinDrug
MitotaneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: every 8 weeks until death up to 5 years
Locations
32 sites in 8 countries. Site status is shown where the registry gives one.
National Cancer Institute - Center for Cancer Research
Bethesda, Maryland
University of Michigan, Department of Internal Medicine
Ann Arbor, Michigan
Royal Adelaide Hospital
Adelaide, Australia
University of Graz
Graz, Austria
Clinique Marc Linquette
Lille, France
Centre Leon Berard
Lyon, France
Hospital de Marseille la timone
Marseille, France
Cochin Hospital
Paris, France
Hospital Bordeaux haut leveque
Pessac, France
Institut Gustave Roussy
Villejuif, France
Charité-University, Dept. of Endocrinology; Campus Benjamin Franklin
Berlin, Germany
Charité-Universitätsmedizin Berlin - Campus Mitte
Berlin, Germany
Dept. of Medicine III
Dresden, Germany
University of Duesseldorf, Dept. of Endocrrinology
Düsseldorf, Germany
Zentrum für Innere Medizin - Endokrinologie des Universitätsklinikum Essen
Essen, Germany
Endokrinologie Medizinische Hochschule Hannover
Hanover, Germany
Otto-von-Guericke University; Dept. of Endocrinology
Magdeburg, Germany
Dept of Medicine I
Mainz, Germany
University of Munich, Dept. of Internal Medicine (Innenstadt)
Munich, Germany
University of Wuerzburg - Dept. of Medicine
Würzburg, Germany
University of Turin, Dept of Internal Medicine
Orbassano, Italy
Clinica Endocrinologica, Università di Padova, Azienda Ospedaliera di Padova
Padova, Italy
Vrije Universiteit Medisch Centrum
Amsterdam, Netherlands
Academisch Medisch Centrum; Dept. of Endocrinology
Amsterdam, Netherlands
Maxima Medisch Centrum; Dept. of Internal Medicine
Eindhoven, Netherlands
University Hospital Groningen; Dept. of Internal Medine
Groningen, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Department of Oncology, Sahlgrenska University Hospital
Gothenburg, Sweden
Department of Oncology, Linköping University Hospital
Linköping, Sweden
Department of Medicine, The Jubileum Institute, Lund University
Lund, Sweden
Dept of Surgery, Karolinska Hospital, Stockholm
Stockholm, Sweden
Uppsala University Hospital - Dept of Medical Sciences
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.